Protara Therapeutics Investor Relations Material
Latest events
Status Update
Protara Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Protara Therapeutics Inc
Access all reports
Protara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing transformative therapies for cancer and rare diseases. Their lead program, TARA-002, is an investigational cell therapy aimed at treating lymphatic malformations, based on the broad immunopotentiator OK-432. Additionally, Protara is developing intravenous choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. The company is headquartered in NYC, and its shares are listed on the Nasdaq.
Key slides for Protara Therapeutics Inc
43rd Annual J.P. Morgan Healthcare Conference 2025
Protara Therapeutics Inc
43rd Annual J.P. Morgan Healthcare Conference 2025
Protara Therapeutics Inc
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
TARA
Country
🇺🇸 United States